Histone H4 Dopaminylation Emerges as a Novel Epigenetic Regulator of Tumor Growth : Nat Chem Biol | May 2026

Introduction

Post-translational modifications are fundamental regulators of gene expression, chromatin organization and cellular behavior. Dopaminylation, a recently identified modification involving covalent attachment of dopamine to glutamine residues on proteins, has emerged as a novel signaling mechanism, although its biologic functions and substrate landscape remain poorly understood.

Problem Statement

The absence of robust methods to comprehensively identify dopaminylated proteins has limited understanding of how dopamine-mediated protein modification influences transcriptional regulation and cancer biology. Whether dopaminylation participates directly in epigenetic control mechanisms and tumor growth regulation has remained largely unknown.

Summary

This study introduces a chemoproteomic platform capable of systematically identifying dopaminylated proteins and substantially expands the known dopaminylation landscape. Using an alkyne-functionalized dopamine probe, the investigators identified more than a thousand putative dopaminylated proteins and characterized histone H4 dopaminylation at glutamine 27 as a previously unrecognized epigenetic modification. Functional analyses demonstrated that H4Q27 dopaminylation acts as a transcriptional repressor in neuroblastoma cells by inhibiting binding of the transcription factor CEBPD at the CCND1 promoter, leading to cyclin D1 suppression and reduced cellular proliferation. These findings establish a direct mechanistic link between dopamine-associated protein modification and chromatin-mediated control of tumor growth. Importantly, the work extends the biologic significance of dopamine beyond neurotransmission and suggests that dopaminylation may represent a broader regulatory system influencing transcriptional programs, cell-cycle progression and oncogenesis. The large-scale substrate dataset generated in this study also provides a major resource for future exploration of dopamine-mediated signaling across multiple physiologic and disease contexts. Overall, this research identifies dopaminylation as an emerging epigenetic mechanism with potential implications for cancer biology and future therapeutic targeting.